Reports
Sale
Alopecia Areata Market Size, Trends, Analysis, Forecast: By Type: Patchy Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Diffuse Alopecia Areata, Ophiasis Alopecia, Others; By Diagnosis: Trichoscopy, Skin Biopsy, Others; By Treatment; By Route of Administration; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Alopecia Areata Market Outlook
The alopecia areata market size is anticipated to grow at a CAGR of 6.3% during the forecast period of 2024-2032, driven by the increased prevalence of hair loss. The growth of the market can also be attributed to the rising efforts for finding novel and better therapies for alopecia areata.
Alopecia Areata: Introduction
Alopecia Areata is an autoimmune disease that targets hair follicles present in the human body resulting in hair loss. The most common area that gets affected by alopecia is the head. There are several sorts of alopecia areata such as patchy alopecia areata, alopecia totalis, alopecia universalis, diffuse alopecia areata, ophiasis alopecia. Some common symptoms of alopecia areata include Patches of hair loss on the affected area, including your scalp, facial hair, eyebrows, eyelashes, body hair, and nail pitting.
Alopecia Areata Market Analysis
The market growth is driven by the increasing incidence of alopecia areata. The market is further influenced by latest FDA approvals for drugs effective in alopecia treatment. For example, the leading pharmaceutical company, Pfizer Inc., received approval from the U.S. Food and Drug Administration (FDA) for LITFULO™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. The approved recommended dose for LITFULO is 50 mg. As it is the one and only FDA approved treatment available, the demand for LITFULO™ is expected to witness a surge in the market. Being the only FDA approved treatment available in the market, it holds the maximum advantage over the Olumiant by Eli Lilly as it covers a wider range of patients. With high demand and widespread market reach the alopecia areata market demand is expected to witness an upward trajectory in the forecast period.
Additionally, Sun Pharmaceutical Industries Ltd. recently declared the acceptance of the new drug application for deuruxolitinib by the U.S. health regulator. This is an investigational oral drug for the treatment of adults with moderate to severe alopecia areata. If approved, this could significantly impact the market by providing an alternative for patients who might not have responded well to existing treatments. Moreover, the introduction of a new drug in the alopecia treatment market could intensify competition, and further contribute to market growth.
Alopecia Areata Market Segmentations
Market Breakup by Type
- Patchy Alopecia Areata
- Alopecia Totalis
- Alopecia Universalis
- Diffuse Alopecia Areata
- Ophiasis Alopecia
- Others
Market Breakup by Diagnosis
- Trichoscopy
- Skin Biopsy
- Others
Market Breakup by Treatment
- Medical Treatments
- Natural Treatment
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Alopecia Areata Market Overview
The alopecia areata market growth is driven by the increasing incidence of alopecia areata. Another significant factor driving the market growth is the rising healthcare expenditure due to which the healthcare facilities are advancing and adopting advanced technologies. The increasing focus of scientists on finding novel and better therapies for alopecia areata has been continuously resulting in a substantial rise in research and development in the field.
Pharmaceutical and biotech companies have an opportunity to fill a crucial gap of unmet needs by creating novel treatments targeting symptoms and potential causes of alopecia areata and encouraging hair regeneration. The substantial growth of awareness among people and patients has led to an increased number of diagnoses for early detection and treatment. This has significantly contributed to the rising alopecia areata market share.
The United States is dominating the regional market due to the increase in surgical hair transplantation among patients suffering from Alopecia areata. The increasing demand for surgical hair transplants has introduced new opportunities for hair restoration clinics. The increasing adoption of advanced technologies in the region is a major factor driving the market growth.
Alopecia Areata Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Johnson & Johnson Services, Inc
- Merck & Co., Inc.
- Cipla Limited
- GlaxoSmithKline plc
- Viatris Inc.
- Pfizer, Inc.
- Curallux, LLC.
- Apira Science Inc.
- Revian Inc.
- Theradome
- Bausch Health Companies Inc.
- Perrigo Company plc
- LEO Pharma A/S
- Hikma Pharmaceuticals PLC
- Baxter
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Diagnosis |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Alopecia Areata Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Alopecia Areata Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Alopecia Areata Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Alopecia Areata Epidemiology Forecast (2017-2032)
5.3.1 Germany Alopecia Areata Epidemiology Forecast (2017-2032)
5.3.2 France Alopecia Areata Epidemiology Forecast (2017-2032)
5.3.3 Italy Alopecia Areata Epidemiology Forecast (2017-2032)
5.3.4 Spain Alopecia Areata Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Alopecia Areata Epidemiology Forecast (2017-2032)
5.4 Japan Alopecia Areata Epidemiology Forecast (2017-2032)
6 Alopecia Areata Market Overview – 7MM
6.1 Alopecia Areata Market Historical Value (2017-2023)
6.2 Alopecia Areata Market Forecast Value (2024-2032)
7 Alopecia Areata Market Landscape – 7MM
7.1 Alopecia Areata: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Alopecia Areata Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
8 Alopecia Areata Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Alopecia Areata Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Alopecia Areata Market Segmentation – 7MM
11.1 Alopecia Areata Market by Type
11.1.1 Market Overview
11.1.2 Patchy Alopecia Areata
11.1.3 Alopecia Totalis
11.1.4 Alopecia Universalis
11.1.5 Diffuse Alopecia Areata
11.1.6 Ophiasis Alopecia
11.1.7 Others
11.2 Alopecia Areata Market by Diagnosis
11.2.1 Market Overview
11.2.2 Trichoscopy
11.2.3 Skin Biopsy
11.2.4 Others
11.3 Alopecia Areata Market by Treatment
11.3.1 Market Overview
11.3.2 Medical Treatments
11.3.3 Natural Treatment
11.3.4 Others
11.4 Alopecia Areata Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Others
11.5 Alopecia Areata Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Others
11.6 Alopecia Areata Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Alopecia Areata Market
12.1 Alopecia Areata Market Historical Value (2017-2023)
12.2 Alopecia Areata Market Forecast Value (2024-2032)
12.3 Alopecia Areata Market by Disease Type
12.4 Alopecia Areata Market by Treatment Type
13 EU-4 and United Kingdom Alopecia Areata Market
13.1 Alopecia Areata Market Historical Value (2017-2023)
13.2 Alopecia Areata Market Forecast Value (2024-2032)
13.3 Germany Alopecia Areata Market Overview
13.3.1 Alopecia Areata Market by Disease Type
13.3.2 Alopecia Areata Market by Treatment Type
13.4 France Alopecia Areata Market Overview
13.4.1 Alopecia Areata Market by Disease Type
13.4.2 Alopecia Areata Market by Treatment Type
13.5 Italy Alopecia Areata Market Overview
13.5.1 Alopecia Areata Market by Disease Type
13.5.2 Alopecia Areata Market by Treatment Type
13.6 Spain Alopecia Areata Market Overview
13.6.1 Alopecia Areata Market by Disease Type
13.6.2 Alopecia Areata Market by Treatment Type
13.7 United Kingdom Alopecia Areata Market Overview
13.7.1 Alopecia Areata Market by Disease Type
13.7.2 Alopecia Areata Market by Treatment Type
14 Japan Alopecia Areata Market
14.1 Alopecia Areata Market Historical Value (2017-2023)
14.2 Alopecia Areata Market Forecast Value (2024-2032)
14.3 Alopecia Areata Market by Disease Type
14.4 Alopecia Areata Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Johnson & Johnson Services, Inc
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Merck & Co., Inc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Cipla Limited
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 GlaxoSmithKline plc
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Viatris Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Pfizer, Inc.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Curallux, LLC.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Apira Science Inc.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Revian Inc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Theradome
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Bausch Health Companies Inc.
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Perrigo Company plc
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 LEO Pharma A/S
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Hikma Pharmaceuticals PLC
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Baxter
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Alopecia Areata Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 6.3% during the forecast period of 2024-2032.
The increasing awareness about alopecia areata, along with the rising research and development activities, are some of the major factors driving the market growth.
The FDA approving drugs for the treatment of conditions is a major trend influencing the market growth.
The 7 major regions of the market include the United States, EU-4, the United Kingdom, and Japan.
There are various types such as patchy alopecia areata, alopecia totalis, alopecia universalis, diffuse alopecia areata, and ophiasis alopecia, among others.
It can be diagnosed by trichoscopy and skin biopsy, and others.
The treatments for alopecia areata can be divided into medical and natural, among others.
Different routes of administration include oral and parenteral, among others.
End users in the market include hospitals and specialty clinics, among others.
Key players involved in the market are Johnson & Johnson Services, Inc, Merck & Co., Inc., Cipla Limited, GlaxoSmithKline plc, Viatris Inc., Pfizer, Inc., Curallux, LLC., Apira Science Inc., Revian Inc., Theradome, Bausch Health Companies Inc., Perrigo Company plc, LEO Pharma A/S, Hikma Pharmaceuticals PLC, and Baxter.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER